The established molecular classification of breast cancer is classically based on the expression of estrogen receptor α (ERα), progesterone receptors (PRs), and overexpression of the human epidermal growth factor receptor 2 (HER2); their presence has been assessed to predict prognosis as well as the potential response to targeted treatments [2,3]. This evidence concerns the gene WNK3 and breast cancer.